Earnings release
Page 1
November 11 , 2021 U UNICYCIVE THERAPEUTICS INC . Unicycive Therapeutics Announces Third Quarter 2021 Financial Results Expect to receive confirmatory guidance on Renazorb regulatory pathway from the U.S. Food and Drug Administration in Q4 2021 LOS ALTOS , Calif . , Nov. 11 , 2021 / PRNewswire / -- Unicycive Therapeutics , Inc. ( Nasdaq : UNCY ) , a clinical stage biotechnology company developing therapies for patients with kidney disease , today reported financial results for the third quarter ended September 30 , 2021 . LUNICYCIVE THERAPEUTICS INC . Shalabh Gupta , M.D. , Chief Executive Officer , stated , " With our addition to the Russell Microcap Index and conference participation , we made meaningful corporate progress to expand the interest and visibility of Unicycive within the investment community last quarter . We are also pleased to have biopharmaceutical executive Douglas Jermasek on our team whose broad experience working with kidney disease treatments has already made a huge impact . " " In chronic kidney disease ( CKD ) , hyperphosphatemia is caused by a chronic dysregulation of phosphates and occurs in at least 70 % of patients with Stage 5 CKD . Current treatments for hyperphosphatemia come with a very high pill burden that can result in poor patient adherence . Our lead program , Renazorb , combines one of the most potent phosphate lowering agents with a smaller , easier swallowed pill to potentially improve the treatment outcomes for patients . We are working with the U.S. Food and Drug Administration ( FDA ) on our regulatory pathway for Renazorb and expect to receive confirmatory guidance in Q4 2021 , " added Dr. Gupta . Key Highlights and Upcoming Milestones • Biopharmaceutical executive Douglas Jermasek appointed as Executive Vice President , Corporate Strategy • Unicycive added to the Russell Microcap Index as part of the 2021 Russell indexes reconstitution • Presented at H.C. Wainwright 23rd Annual Global Investment Conference • Upcoming presentation at the Benchmark Discovery One on One Investor Conference • Expect to receive confirmatory guidance on Renazorb regulatory pathway from the